Answers are grounded in this paper and cite their sources.
Translational study demonstrates reduced relapse, graft rejection, and GVHD from donor NK-cell alloreactivity in hematopoietic transplants, indicating a safer graft approach.
T cells that accompany allogeneic hematopoietic grafts for treating leukemia enhance engraftment and mediate the graft-versus-leukemia effect. Unfortunately, alloreactive T cells also cause graft-versus-host disease (GVHD). T cell depletion prevents GVHD but increases the risk of graft rejection and leukemic relapse. In human transplants, we show that donor-versus-recipient natural killer (NK)-cell alloreactivity could eliminate leukemia relapse and graft rejection and protect patients against GVHD. In mice, the pretransplant infusion of alloreactive NK cells obviated the need for high-intensity conditioning and reduced GVHD. NK cell alloreactivity may thus provide a powerful tool for enhancing the efficacy and safety of allogeneic hematopoietic transplantation.
No takes yet. Share an insight, caveat, or question.
Ruggeri et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: